INDIVIDUAL PRE-CLINICAL STUDIES AND RESULTS
What does the Peptide Do?
Weight Gain and Blood Glucose
- Pre-clinical evaluation for 14 days in female (Male given Obsto Peptide: -16%) rodents at maximum tolerated dose. Amlexanox and AOD9604 are peptides known for fat burning.
- The comparison is between different studies. Peptide data is generated by a third party research organization, TOXI-COOP ZRT, following OECD Guidelines for Testing of Chemicals and US FDA Toxicological Principles. Amlexanox reference: Nat Med. 2013 Mar;19(3):313-21, AOD9604 reference: Endocrinology 142(12):5182–5189.
- AOD9604 is one of the few FDA GRAS approved peptides.
- Administration routes: Obsto peptide-Oral, Amlexanox and AOD9604 syringe injection.
g food/animal/day
DECREASED BODY WEIGHT GAIN
DECREASED BLOOD GLUCOSE
OBSTO PEPTIDE INCREASES FOOD PROCESSING EFFICIENCY WITH NO CHANGE IN APPETITE
No increase in appetite, but increased food efficiency
- Food processing efficiency=g food consumed/g body weight gain. Higher number indicates that body processes the food consumed more efficiently through increased energy expenditure, expedited elimination, and/or reduced accumulation, etc. For example, food processing efficiency=1.0 indicates the 100% of food consumed goes to body weight.
FOOD CONSUMPTION
FOOD PROCESSING EFFICIENCY
HOW DOES THE Obsto Peptide work?
- Pre-clinical evaluation for 30 days in half male and half female rodents at 100 μg/animal. Sugar and lipid (fat) concentrations in fat cells were measured in fat cells.
REDUCED SUGAR/FAT IN FAT CELL
REDUCED SIZE OF FAT CELLS
- Average size of fat cells decreased by 12%
- Number of fat cells/1mm2 increased by 20%
124 cells/hpf; 3995 µm2/cell 100 cells/hpf; 4448 µm2/cell
Obsto peptide
Water
Does the peptide work through skin?
- Obsto Peptide dissolved in commercially available body products applied transdermal on forearm, waist, hip and thigh. Clinical evaluation for 30 days, once/day applications at 0.3 mg/day Obsto Peptide. Average values, n=10.
REDUCED SUBCUTANEOUS FAT
Boosts Immunity
- Left: Pre-clinical evaluation for 10 days in obese rodents with melanoma tumor. Fold increase in tumor indicates the tumor growth relative to the tumor size at the beginning. Data is re-generated from Dr. Won’s publication, Pharmaceutics (2021, 13, 1279).
- Right: Pre-clinical evaluation for 30 days in non-obese rodents with melanoma tumor. Animals were given water, Durvalumab (anti-PD-L1 immunotherapy approved by FDA), or Obsto Peptide + Durvalumab. Fold increase in tumor indicates the tumor growth relative to the tumor size at the beginning. Data is re-generated from Dr. Yongwook Won’s unpublished data (confidential).
BOOSTED INNATE IMMUNITY
BOOSTED IMMUNOTHERAPY
